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Rapidly growing ovarian endometrioid adenocarcinoma involving
the vagina: A case report
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Accepted 19 August 2010AbstractObjective: We present a rare case of a very rapidly growing stage IV ovarian endometrioid adenocarcinoma involving the uterine cervix and
vagina without lymph node involvement.
Case Report: A 43-year-old woman visited the hospital with complaints of lower abdominal discomfort and vaginal bleeding over the previous
3 months. Serum levels of tumor marker CA 125 and SCC antigen (TA-4) were normal. On magnetic resonance imaging, a 7.9 9.7 cm
heterogeneous mass with intermediate signal intensity was observed in the posterior low body of the uterus. Two months ago, a computed
tomography scan revealed an approximate 4.5 3.0 cm heterogeneously enhanced subserosal mass with internal ill-defined hypodensities. A
laparotomy, including a total abdominal hysterectomy with resection of the upper vagina, bilateral salpingo-oophorectomy, pelvic and para-
aortic lymph node dissection, appendectomy, total omentectomy, and biopsy of rectal serosa was performed. A histological examination
revealed poorly differentiated endometrioid ovarian adenocarcinoma with vaginal involvement. The patient had an uncomplicated post-operative
course. After discharge, she completed six cycles of adjuvant chemotherapy with paclitaxel (175 mg/m2) and carboplatin (300 mg/m2) and has
remained clinically disease-free until June 2010.
Conclusion: Epithelial ovarian cancer may grow very rapidly. The frequent measurement of tumor size by ultrasonography may provide
important information on detection in a subset of ovarian carcinomas that develop from preexisting, detectable lesions.
Copyright  2011, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Ovarian cancer is the leading cause of death from gyne-
cological malignancy in most developed countries, although it
is still relatively infrequent in developing countries. In the
USA, ovarian cancer is the fifth leading cause of cancer-
related death among women and the leading cause of gyne-
cological cancer deaths, accounting for nearly 16,000 deaths
in 2008 [1]. Over 90% of all ovarian cancers are epithelial in
type histologically [2]. Endometrioid carcinoma of the ovary* Corresponding author. Department of Obstetrics and Gynecology,
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E-mail address: obypf@kangwon.ac.kr (D. Lee).
1028-4559/$ - see front matter Copyright  2011, Taiwan Association of Obstetri
doi:10.1016/j.tjog.2011.10.023is a specific histopathological entity that accounts for 16e25%
of epithelial ovarian cancer.
Generally, epithelial ovarian cancer grows rapidly and
presents as advanced disease at the time of diagnosis because
patients do not experience symptoms in the early stages [3, 4].
However, it generally takes about 3e6 months for a cancer to
double in volume [5]. A previous study developed models for
the growth, progression, and detection of occult serous cancers
based on a comprehensive analysis of published data on serous
cancers discovered by prophylactic bilateral salpingo-
oophorectomy (PBSO) in BRCA1 mutation carriers [6].
However, to our knowledge, no report has been published on
rapidly growing endometrioid ovarian cancer. In this study, we
report a case of an endometrioid carcinoma of the ovary,
which grew very rapidly and caused metastases to the uterine
cervix and the vagina without lymph node involvement.cs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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On December 9, 2009, a 43-year-old woman (gravida 2,
para 2) presented to the Department of Obstetrics and Gyne-
cology in Kangwon National University Hospital with
complaints of lower abdominal discomfort and vaginal
bleeding over the previous 3 months. Her usual menstrual
cycle was regular at 30 days, and her menstruation was
moderate. Although she had mild dysmenorrhea, she had not
taken any pain medication. She had her first period at the age
of 13. Her medical and family histories were not significant.
She had previously visited a private obstetric and gyneco-
logic clinic with complaints of spotting and abdominal
distention on September 3, 2009. She underwent a screening
examination including a pelvic examination and transvaginal
ultrasonography (USG). An approximately 2.4 2.0 cm
mixed echogenic density was observed on the left side of the
posterior cervix of the uterus, which was suspicious of
a cervical myoma (Fig. 1), but no other abnormalities were
found in the uterus or either ovary. A Pap smear of the cervix
was conducted, and the results were normal. Two days later,
because symptoms persisted, she underwent an explorative
pelviscopic operation, which revealed an adhesion between the
left ovary and the posterior wall of the uterus and an
approximate 3.5 2.0 cm cystic mass in the left ovary. No
other gross abnormality was observed in the pelvic cavity,
including the right ovary. A pelviscopic left ovarian cys-
tectomy was performed, and the cyst was pathologically
diagnosed to be an endometrioma. Two days later, she was
discharged without any events. On the 7th day after the
operation, a postoperative follow-up transvaginal USG showed
nothing abnormal.Fig. 1. Transvaginal ultrasonography finding on the first visit. An approximate 2.4
cervix of the uterus is suspicious of a cervical myoma (arrow).However, her symptoms continued and brought her to the
Chuncheon Sacred Heart Hospital on September 30, 2009.
Diagnostic procedures, including a pelvic examination, tumor
marker (AFP, CA 19-9, and CA 125) analysis, gastroscopy,
colonoscopy, chest X-ray, and an abdominal and pelvic
computed tomography (CT) scan were conducted. The pelvic
examination, tumor markers, endoscopy, and chest X-ray
revealed nothing abnormal. The CT scan showed an approxi-
mate 4.5 3.0 cm heterogeneously enhanced subserosal mass
with internal ill-defined hypodensities and a circumferential
rim in the posterior wall of the uterus (Fig. 2), suggesting
a degenerated uterine myoma, an endometrioma, or, less
likely, an exophytic growing cervical cancer. The right adnexa
adhered to the uterine mass so closely, that it was difficult to
draw clear lines of demarcation between the right adnexa and
the uterine mass. The CT scan failed to show any other
specific findings in the abdominal or pelvic cavities, including
the left adnexa. Because the spotting had stopped, she was
discharged without any therapeutic procedures.
One month later, vaginal bleeding restarted and continued
for 1 month, so she visited Kangwon National University
Hospital. She appeared chronically ill, and showed a weight
loss from 53.0 to 50.4 kg over the previous 3 months. No gross
abnormal findings in the chest and abdomen were noted. On
pelvic examination, she had a large, hemorrhagic, friable mass
that seemed to originate from the anterior fornix and extended
to the upper vaginal wall. A rectovaginal exam was negative.
Colposcopically, a 3e4 cm sized exophytic mass covering the
right side of the upper vagina and cervix was found (Fig. 3).
Because the mass was friable and highly vascular, with
multiple bleeding foci, it was difficult to identify the tumor
origin. A punch biopsy of the tumor showed massive tumor 2.0 cm mixed echogenic density observed in the left side of the posterior
Fig. 2. Computed tomography findings of September 30, 2009. Arrow shows
an approximate 4.5 3.0 cm heterogeneously enhanced subserosal mass with
internal ill-defined hypodensities and a circumferential rim in the posterior
wall of the uterus.
Fig. 4. Microscopic findings of the tumor showing: (A) tumor cell nests
(arrow) and (B) squamoid differentiation (arrow).
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appeared more likely to be a non-keratinizing invasive squa-
mous cell carcinoma originating from the cervix, but carci-
noma from the ovary could not be excluded. Because the
origin of the tumor was unclear, the final diagnosis was
pending at that time.
Serum levels of tumor marker CA 125 and SCC antigen
(TA-4) were 14.3 U/mL and 1.02 ng/mL, respectively. Her
chest radiograph was normal. A magnetic resonance image
revealed a 7.9 9.7 cm heterogeneous mass, with interme-
diate signal intensity in the posterior lower body of the uterus
(Fig. 5). The uterine cervical structure had no well-defined
features, and the center of the mass was located in the
posterior lower body of the uterus. The mass seemed to
involve the proximal rectum and abutted the vagina. AFig. 3. Colposcopic finding on December 9, 2009 shows a 3e4 cm exophytic
mass covering the right side of the upper vagina and cervix.sigmoidoscopy detected no abnormality in the mucosa, but
extrinsic compression was seen in the left lateral wall of the
rectum. An intravenous pyelogram showed no radiopaque
lesion or filling defect in the bilateral opacified renal pelvo-
calyces, bilateral ureters, or the opacified bladder.
A laparotomy was performed on December 14, 2009. A
small amount of ascites was found in the peritoneal cavity. An
approximate 6 cm right ovarian mass was adhered to the
posterior aspect of the lower uterine segmental mass, which
was estimated to be about 10 cm in size. This mass perforated
the lumen of the upper right side of the vagina (Fig. 6.). The
transformation zone of the cervix and cervical canal seemed to
be grossly intact. The pelvic mass had adhered to the rectum,
but no involvement of the omentum, intestines, or pelvic
cavity peritoneum was observed. A total abdominal hyster-
ectomy, including resection of the upper vagina, bilateral
salpingo-oophorectomy, pelvic and para-aortic lymph node
dissection, appendectomy, total omentectomy, and biopsy of
the rectal serosa, was conducted. The ascites cytology showed
no tumor cells.
Fig. 5. MR (A) sagittal and (B) axial images on December 10, 2009. A
7.9 9.7 cm heterogeneous mass with intermediate signal intensity is seen in
the posterior low body of the uterus (arrows). The uterine cervical structure has
poorly defined features, and the center of the mass is located in the posterior
low body of the uterus.
Fig. 6. (A) Anterior and (B) posterior gross findings of the specimen. An
approximate 6-cm right ovarian mass was adhered to the posterior aspect of
the lower uterine segmental mass, which was estimated to be about 10 cm.
This mass perforated the lumen of the upper right side of the vagina.
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extended to the lower uterine segment, the uterine cervix, the
vaginal wall, and the rectal serosa, but no involvement of the
left ovary, fallopian tube, or the uterine endometrium was
found. Metastases were not found in any of the 38 retrieved
lymph nodes. Immunohistochemical examinations to deter-
mine the tumor origin were performed. Cytokeratin staining
was positive, whereas staining for cytokeratin-7/20, inhibin,
calretinin, smooth muscle actin (SMA), and carcinoembryonic
antigen (CEA) were negative. Epithelial membrane antigen
(EMA) and vimentin staining were focally positive. The final
diagnosis was poorly differentiated endometrioid ovarian
adenocarcinoma, with focal squamoid differentiation.She had an uncomplicated post-operative course. After
discharge, she completed six cycles of adjuvant chemotherapy
with paclitaxel (175 mg/m2) and carboplatin (300 mg/m2).
After treatment, she remained clinically disease-free until June
2010. The clinical course of the patient is summarized as
a flow chart (Fig. 7).Discussion
It is generally believed that solid tumors such as ovarian
cancer start from a single malignant cell, and exponential
growth occurs early in the history of the tumor. Some factors
influence the rate of tumor growth. For example, advanced stage
tumors grow more rapidly than early stage tumors, and meta-
static lesions generally have a faster doubling time than primary
lesions [5]. Histological type can also influence the growth rate;
germ cell tumors, lymphomas, and malignant mesenchymal
tumors are relatively fast-growing tumors (doubling time,
Fig. 7. A flow-chart showing the clinical course of the patient.
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nomas grow more slowly (doubling time, 50e150 days) [5].
Data from the literature concerning the growth rate of ovarian
carcinoma are scarce. Brown and Palmer estimated the growth
rates of early-stage and late-stage (stage III and IV) serous
ovarian tumors using the Monte Carlo method. According to
their analyses, early stage ovarian cancers double in volume
approximately every 4 months, whereas advanced-stage tumors
double involume approximately every 2.5months [6]. If a tumor
grows faster, it is more likely an infection than a cancer, and if it
grows slower, the possibility that it is a cancer is low. In this
study, we reported on a very rapidly growing endometrioid
ovarian cancer. Although we could not find a previous study
reporting the growth rate of endometrioid ovarian carcinomas,
we assumed that it might be similar to that of serous ovarian
cancer, because both are epithelial in origin.
In the present case, the right ovarian mass, suspected as
a degenerated uterine myoma on the CT scan, seemed to grow
to a 4.5 3.0 cm tumor in 1 month, as the right ovary was
macroscopically normal on a previous laparoscopy. Further-
more, about 2 months later, the tumor had enlarged to 10 cm,
which was an increase of about three times in diameter,
comparable to a 20e30 fold increase in volume. Considering
that typical advanced-stage ovarian tumors double in volume
approximately every 2.5 months, the growth rate of our case
was extraordinary, more than 10-fold the normal growth rate.
Kobayashi et al reported on an ovarian tumor that grew from 5
to 14 cm in diameter in only 4 weeks [7]. Compared with our
case, the growth rate of that tumor seemed to be more rapid.
But we still believe that our case is worth reporting, because
their patient developed the tumor during pregnancy. Because
the levels of gonadotropins and steroid hormones change
markedly during pregnancy, a malignant neoplasm can grow
much more rapidly under such a condition [7]. Cuesta et alsuggested that an endometrioid adenocarcinoma coexisting
with endometriosis has a favorable prognosis [8]. The pres-
ence of pelvic endometriosis may contribute to the early
diagnosis of ovarian cancer because of symptoms, including
pain and dysmenorrhea. Another study suggested that the
coexistence of an endometriotic lesion might serve as a nega-
tive influence on the intraperitoneal spread of the localized
cancer cells in the ovary [9]. Nevertheless, our patient was
diagnosed as stage IV due to direct invasion to the vaginal
lumen, which may be additional evidence of the extraordi-
narily rapid growth of the tumor in this case.
It is not clear whether the ovarian cancer originated from
endometriosis or de novo. In fact, the coincidence of endo-
metriosis and endometrioid ovarian cancer has been
mentioned in several reports since 1928 [10]. Endometriosis is
found in approximately 10% of premenopausal women, but is
present in 10e15% of patients with ovarian cancer [11, 12].
Endometrioids, clear-cell carcinomas, and mixed subtypes are
pathologically common in neoplasms arising from endome-
triosis [13]. The incidence of ovarian endometrioma in ovarian
cancer occurs as follows: 3.3%, serous type; 3.0%, mucinous
type; 21.2%, endometrioid type; 39.2%, clear-cell adenocar-
cinoma [9]. A malignant transformation of endometriosis is
thought to occur in 0.7e1.0% of all cases [14]. Sampson, who
first described a possible association between endometriosis
and carcinoma of the ovary, defined the following criteria for
diagnosing a malignant transformation of endometriosis: (1)
a clear example of the endometriosis in proximity to the tumor
must be found; (2) no other primary site for the tumor can be
found; and (3) the histological appearance must be consistent
with an origin from endometriosis [13]. Based on this
perspective, it seems difficult to conclude that malignant
transformation occurred in this case, as endometriosis was
initially diagnosed on the left side, whereas the cancer was
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ovarian cyst was diagnosed histologically as endometrioma on
a previous laparoscopy, we cannot exclude the possibility that
endometrioid ovarian cancer may have coexisted with the
benign lesion. According to the patient’s first time operation
record, a left ovarian cyst, enlarged to 3e3.5 cm, was admixed
with the small intestine and adhered to the lower posterior
portion of the uterus. It is possible that the posterior cul-de-sac
might have been at least partially obliterated. In such condi-
tions, due to technical limitations, the surgeon might not open
the surgical field enough for the proper diagnosis. It may be
that only a benign lesion was included in the specimen for the
histological exam. An adhesion between the left ovary and the
uterus may have helped cryptic cancer cells to invade the
uterus and right ovary directly. Incomplete first time surgery
might debulk only the benign portion of the tumor and
augment the growth rate of crypt cancer cells. De novo
carcinogenesis is also possible in the development of endo-
metrioids and the clear-cell type of ovarian carcinoma [15].
A distant metastasis (stage IV disease) is unusual, but it may
occur at the time of diagnosis of ovarian cancer, or can arise
during evolution of the disease. In a previous study, distant
metastases were present in 8% of the patients at the time of
diagnosis and in 22% of the patients during the disease course
[16]. When these tumors metastasize, they usually initially
metastasize to the retroperitoneal lymph nodes [17]. A distant
metastasis is usually associated with widespread disseminated
disease and poor performance status; the effects of this rare
metastasis are devastating, and survival is usually very poor
[17]. Distant metastases theoretically may occur anywhere;
however, the pleura, liver, lung, central nervous system, spleen,
skin, bone, and breast are, decreasing in order, the most
commonly involved sites [16]. This case was diagnosed as stage
IV, due to direct vaginal invasion. Ovarian cancer rarely
metastasizes to the uterine cervix, vagina, or vulva. So, vaginal
invasion is an interesting pattern of distant metastasis in this
case of ovarian cancer. Bergman’s autopsy series documented
11 cases of vaginal spread of ovarian carcinoma [18]. It was
suggested that the lymphatics may convey tumors from the
ovary to the vagina, as described by Willis [19]. However, in all
of Bergman’s cases, the pelvic peritoneum was involved with
tumor masses in the pouch of Douglas, from which the carci-
noma could infiltrate the vagina, which is a similar metastasis
pattern to our case. Most cases of ovarian carcinoma spread
through the retroperitoneal lymphatics. Ovarian cancer gener-
ally causes ascites or bowel adhesions, but peritoneal and distant
metastases seldom occur in the absence of intra-abdominal
disease [16]. Interestingly, in our case, direct vaginal invasion
occurred without formation of malignant ascites or lymph node
involvement. It seemed that the speed of extension was so rapid
that cancer could invade the uterine cervix and vagina before
metastasis to the lymphatics and blood vessels. Unfortunately, it
is unclear what made the cancer grow and invade the neigh-
boring organs so quickly. Further studies are needed.
In our case, the patient’s tumor marker levels were within
normal ranges, and the tumor showed nonspecific findings on
the USG even 3 months before diagnosis. Although it is wellknown that serous or other histological types of ovarian
carcinomas that appear to develop from a normal-appearing
ovary cannot be detected even by careful examination using
transvaginal USG [20], the frequent measurement of tumor
size by USG may provide important information on detection
in a subset of ovarian carcinomas that develop from preex-
isting, detectable lesions. Presently, no practical option seems
to be available except frequent measurements of tumor size
by USG and checking serum tumor marker levels for the
management of a pelvic mass.References
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